Ovid Therapeutics Inc. (OVID) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ovid Therapeutics Inc. (OVID)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.77

-0.03 (-4.23%)

At close: Jan 14, 2025, 3:59 PM

0.79

3.15%

After-hours Jan 14, 2025, 05:05 PM EST

undefined% (undefined)

Bid	0.67
Market Cap	54.71M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.46
PE Ratio (ttm)	-1.67
Forward PE	n/a
Analyst	Buy

Ask	1.21
Volume	249,555
Avg. Volume (20D)	268,904
Open	0.79
Previous Close	0.80
Day's Range	0.76 - 0.81
52-Week Range	0.68 - 4.10
Beta	undefined

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 5, 2017

Employees 25

Stock Exchange NASDAQ

Ticker Symbol OVID

Website https://www.ovidrx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 289.41% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ovid Therapeutics Inc. is scheduled to release its earnings on Mar 7, 2025, before market opens.
Analysts project revenue of $100.00K, reflecting a -29.36% YoY shrinking and earnings per share of -0.18, making a -18.18% decrease YoY.

Why Price Moved

7 months ago · Source

-76%

Ovid Therapeutics shares are trading lower after T... Unlock content with Pro Subscription

News

2 months ago · zacks.com

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.